MRI contrast developer Epix Medical reported that the initial purchasers of its $75 million in notes have exercised their over-allotment option to purchase an additional $25 million in notes, due in 2024.
The Cambridge, MA-based firm expects the closing of the sale to occur on June 7, which will result in proceeds of approximately $96 million to the company after initial purchasers' discount and issuance costs, Epix said.
By AuntMinnie.com staff writersJune 4, 2004
Related Reading
Epix floats new debt, June 2, 2004
Epix trims losses in Q1, April 30, 2004
Epix names McMurry as research VP, March 12, 2004
Epix loss falls, sales rise in 2003, February 18, 2004
Epix gets U.S. patent for MS-325, January 13, 2004
Copyright © 2004 AuntMinnie.com
